I'm Buying BMOD

For your perusal, BMOD. I am looking to buy this around a quarter.

Biomoda Website
BMOD Ticker

From Biomed Reports:
On 8/4/09, Biomoda (BMOD.OB) ($0.23) announced that 500 New Mexico veterans have committed to participate in a state-funded program for the detection of early-stage lung cancer based on the Company’s proprietary technology, which is currently in development as an inexpensive, simple, and highly accurate in-vitro test for early detection of lung cancer. The assay is based upon Biomoda’s patent estate centered on molecular marker technology, originally developed at Los Alamos National Labs. Internal validation testing results have shown near 100% accuracy of the assay with no false positives or false negatives. Eventual commercial level accuracy in the 90% range is to be reasonably expected compared to PAP staining which is 64% accurate.

Biomoda submitted a Pre-IDE to the FDA who responded favorably, and the Company’s Phase 2 Clinical Trial is underway as part of a larger screening program[/B] in partnership with the New Mexico Department of Veterans Services (NMDVS) and New Mexico Tech (NMT) to screen veterans for lung cancer in New Mexico. Biomoda has enrolled over 500 participants in the program and have run more than 90 through the collection procedure with results of this 300+ patient study expected in the fall of 2009 (the 10/31/09 date for this entry is only an estimate within this timeframe). The study will be expanded to 3,500 patients thereafter as a Phase 3 Pivotal Clinical Trial, with results of the larger study expected in 2010. Biomoda and NMT are developing an automated technology to support large-population screening for cancer. Results from these studies will be sufficient to submit to FDA for final approval as a Class III PMA IVO device, which is expected to occur in 2011.

From Trading Markets:
August 7, 2009 (FinancialWire) -- Biomoda, Inc. (OTCBB: BMOD), the New Mexico Department of Veterans Services, and the New Mexico Institute of Mining and Technology (NM Tech) appeared before the State Legislature's Interim Tobacco Settlement Committee to report that 500 New Mexico veterans have committed to participate in a state-funded program for the detection of early-stage lung cancer based on Biomoda's proprietary technology.
John Cousins, Biomoda president and CEO, told the legislators that the $1.65 million appropriated for the screening program has raised awareness among New Mexico veterans of the U.S. armed forces about their increased risk for developing lung cancer and the importance of early detection. Of the 500 volunteers for the program, more than 100 have completed the screening.
Biomoda's diagnostic is based on a patented molecular marker originally developed at Los Alamos National Laboratory that preferentially binds to cancerous or aberrant cells and causes them to fluoresce under ultraviolet light. Under the guidance of a respiratory therapist, study volunteers provide a deep-lung sputum sample to be processed with Biomoda's CyPath(r) assay in the Biomoda lab. Results are compared to a CT scan and PAP stains read by cytopathologists to confirm accuracy.
"This study will help us move the CyPath(r) technology closer to FDA approval and commercialization, bringing a non-invasive, accurate, and inexpensive tool for detecting cancer to market," Cousins said. "The health benefits of the Biomoda diagnostic are obvious and have worldwide implications."

There was a huge run up after BMOD was profiled in a few investor newsletters, including Stockshaven.